Status of the hormone receptors, which predicts the response to hormonal therapy, and human epidermal growth factor receptor 2 (HER2) expression, which predicts the response to anti-HER2 therapy in patients with HER2-positive breast cancer, were confirmed to be reliable predictive factors in breast cancer. Here, NR4A1 is linked to breast carcinoma.